CIK 0001842295 · Non-accelerated filer<br>Emerging growth company
Maze Therapeutics, Inc.
Sign in to watch- Ticker
- MAZE
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 6508505070
- Business address
- 171 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO, CA, 94080
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $5,785,701
- in 13 filings, $4.6M under 10b5-1 plans
Net −$5,785,701. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-12-09 | HOMCY CHARLES J Director | Grant or award · Stock Option (Right to Buy) | +5,704 | 5,704 | ||
| 2024-12-09 | HOMCY CHARLES J Director | Returned to the company · Stock Option (Right to Buy) | −5,704 | 0 | ||
| 2024-12-09 | HOMCY CHARLES J Director | Grant or award · Stock Option (Right to Buy) | +46,675 | 46,675 | ||
| 2024-12-09 | HOMCY CHARLES J Director | Returned to the company · Stock Option (Right to Buy) | −46,675 | 0 | ||
| 2024-12-09 | HOMCY CHARLES J Director | Grant or award · Stock Option (Right to Buy) | +45,638 | 45,638 | ||
| 2024-11-26 | HOMCY CHARLES J Director | Conversion · Series D-1 Preferred Stock | +71,564 | 7,422 | ||
| 2024-11-26 | HOMCY CHARLES J Director | Conversion · 8% Convertible Note due 2026 | −0 | $78,961.64 | $0 |
Page 14 of 14 · 267 trades